Baicalein Inhibits the Invasion and Metastatic Capabilities of Hepatocellular Carcinoma Cells via Down-Regulation of the ERK Pathway

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Chen, Kunlun ^a   Zhang, Shu ^a   Ji, Yuanyuan ^a   Li, Jun ^a   An, Peng ^a   Ren, Hongtao ^a   Liang, Rongrui ^a,b   Yang, Jun ^a   Li, Zongfang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BAICALEIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME DEGRADATION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883645320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072927     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. doi:10.3322/canjclin.55.2.74. PubMed: 15761078.
2. Llovet JM, Bisceglie Di, AM, Bruix J, Kramer BS, Lencioni Ret al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711. doi:10.1093/jnci/djn134. PubMed: 18477802.
3. Bruix J, Sherman M, (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022. doi:10.1002/hep.24199. PubMed: 21374666.
4. Tang ZY, (2005) Hepatocellular carcinoma surgery--review of the past and prospects for the 21st century. J Surg Oncol 91: 95-96. doi:10.1002/jso.20291. PubMed: 16028278.
5. Gialeli C, Theocharis AD, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27. doi:10.1111/j.1742-4658.2010.07919.x. PubMed: 21087457.
6. Iguchi K, (2012) [Effect of bisphosphonates on anticancer activity in prostate cancer cells]. Yakugaku Zasshi 132: 1025-1030. doi:10.1248/yakushi.132.1025. PubMed: 23023419.
7. Okada A, (1999) [Roles of matrix metalloproteinases and tissue inhibitor of metalloproteinase (TIMP) in cancer invasion and metastasis]. Gan To Kagaku Ryoho 26: 2247-2252. PubMed: 10635313.
8. Murphy G, (2011) Tissue inhibitors of metalloproteinases. Genome Biol 12: 233. doi:10.1186/gb-2011-12-11-233. PubMed: 22078297.
9. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822. doi:10.1038/sj.onc.1202367. PubMed: 9989833.
10. Shimizu T, Torres MP, Chakraborty S, Souchek JJ, Rachagani S, et al. (2013) Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy. Cancer Lett, 336: 270-80. PubMed: 23523869.
11. Deng W, Sui H, Wang Q, He N, Duan C, et al. (2013) A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways. BMC Complement Altern Med 13: 65. doi:10.1186/1472-6882-13-65. PubMed: 23506655.
12. Wang Q, Tang H, Yin S, Dong C, (2013) Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29: 2046-2052. PubMed: 23446431.
13. Bessard A, Frémin C, Ezan F, Coutant A, Baffet G, (2007) MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 212: 526-536. doi:10.1002/jcp.21049. PubMed: 17427199.
14. Liu B, Wang G, Yang J, Pan X, Yang Z, et al. (2011) Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLOS ONE 6: e21416. doi:10.1371/journal.pone.0021416. PubMed: 21738655.
15. Liang RR, Zhang S, Qi JA, Wang ZD, Li J, et al. (2012) Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. Int J Oncol 41: 969-978. PubMed: 22684543.
16. Ma Y, Yu WD, Trump DL, Johnson CS, (2010) 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116: 3294-3303. doi:10.1002/cncr.25059. PubMed: 20564622.
17. Xu L, Deng X, (2006) Protein kinase Ciota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of micro- and m-calpains. J Biol Chem 281: 4457-4466. doi:10.1074/jbc.M510721200. PubMed: 16361262.
18. Hazama S, Noma T, Wang F, Iizuka N, Ogura Y, et al. (1999) Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br J Cancer 80: 1420-1426. doi:10.1038/sj.bjc.6690538. PubMed: 10424745.
19. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, et al. (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66: 239-243. doi:10.1002/(SICI)1097-0215(19960410)66:2. PubMed: 8603818.
20. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, et al. (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81: 814-821. doi:10.1038/sj.bjc.6690769. PubMed: 10555751.
21. Puxbaum V, Mach L, (2009) Proteinases and their inhibitors in liver cancer. World J Hepatol 1: 28-34. doi:10.4254/wjh.v1.i1.28. PubMed: 21160962.
22. Min L, He B, Hui L, (2011) Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 21: 10-20. doi:10.1016/j.semcancer.2010.10.011. PubMed: 20969960.
23. Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, et al. (2013) Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol 182: 954-964. doi:10.1016/j.ajpath.2012.11.019. PubMed: 23306155.
24. Xiao LJ, Lin P, Lin F, Liu X, Qin W, et al. (2012) ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724. PubMed: 22200661.
25. Fields J, Cisneros IE, Borgmann K, Ghorpade A, (2013) Extracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1beta-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression. PLOS ONE 8: e56891. doi:10.1371/journal.pone.0056891. PubMed: 23457635.
26. Liu S, Yu M, He Y, Xiao L, Wang F, et al. (2008) Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 47: 1964-1973. doi:10.1002/hep.22240. PubMed: 18506888.
27. Tang Z, Zhou X, Lin Z, Yang B, Ma Z, et al. (1999) Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin Med J (Engl) 112: 887-891. PubMed: 11717970.
28. Chandrashekar N, Selvamani A, Subramanian R, Pandi A, Thiruvengadam D, (2012) Baicalein inhibits pulmonary carcinogenesis-associated inflammation and interferes with COX-2, MMP-2 and MMP-9 expressions in-vivo. Toxicol Appl Pharmacol 261: 10-21. doi:10.1016/j.taap.2012.02.004. PubMed: 22369883.
29. Wu B, Li J, Huang D, Wang W, Chen Y, et al. (2011) Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells. BMC Cancer 11: 527. doi:10.1186/1471-2407-11-527. PubMed: 22204275.
30. Wang ZD, Huang C, Li ZF, Yang J, Li BH, et al. (2010) Chrysanthemum indicum ethanolic extract inhibits invasion of hepatocellular carcinoma via regulation of MMP/TIMP balance as therapeutic target. Oncol Rep 23: 413-421. PubMed: 20043102.
31. Du G, Han G, Zhang S, Lin H, Wu X, et al. (2010) Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1alpha inhibition. Eur J Pharmacol 630: 121-130. doi:10.1016/j.ejphar.2009.12.014. PubMed: 20036231.
32. Chen CH, Huang LL, Huang CC, Lin CC, Lee Y, et al. (2000) Baicalein, a novel apoptotic agent for hepatoma cell lines: a potential medicine for hepatoma. Nutr Cancer 38: 287-295. doi:10.1207/S15327914NC382_19. PubMed: 11525608.
33. Friedl P, Wolf K, (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374. doi:10.1038/nrc1075. PubMed: 12724734.
34. Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, et al. (2011) Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer 11: 140. doi:10.1186/1471-2407-11-140. PubMed: 21496284.
35. Arii S, Mise M, Harada T, Furutani M, Ishigami S, et al. (1996) Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24: 316-322.
36. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, et al. (2000) Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15: 422-430. doi:10.1046/j.1440-1746.2000.02150.x. PubMed: 10824888.
37. Tryggvason K, Höyhtyä M, Salo T, (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191-217. PubMed: 2823896.
38. Yang SF, Chen MK, Hsieh YS, Yang JS, Zavras AI, et al. (2010) Antimetastatic effects of Terminalia Catappa L. on oral cancer via a down-regulation of metastasis-associated proteases. Food Chem Toxicol 48: 1052-1058. doi:10.1016/j.fct.2010.01.019. PubMed: 20102732.
39. Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC, (2008) Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis 29: 147-156. PubMed: 18024477.
40. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, et al. (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17: 177-181. doi:10.1023/A:1006603723759. PubMed: 10411111.
41. Kim J, Yu W, Kovalski K, Ossowski L, (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353-362. doi:10.1016/S0092-8674(00)81478-6. PubMed: 9708737.
42. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, et al. (2002) Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97: 425-431. doi:10.1002/ijc.1635. PubMed: 11802202.
43. Martin DC, Rüther U, Sanchez-Sweatman OH, Orr FW, Khokha R, (1996) Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 13: 569-576. PubMed: 8760297.
44. Cohen M, Meisser A, Haenggeli L, Bischof P, (2006) Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. Mol Hum Reprod 12: 225-232. doi:10.1093/molehr/gal023. PubMed: 16520344.
45. Liu SQ, Huang JA, Qin MB, Su YJ, Lai MY, et al. (2012) Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways. Int J Colorectal Dis 27: 1569-1578. doi:10.1007/s00384-012-1510-y. PubMed: 22684547.
46. Chen YY, Liu FC, Chou PY, Chien YC, Chang WS, et al. (2012) Ethanol Extracts of Fruiting Bodies of Antrodia cinnamomea Suppress CL1-5 Human Lung Adenocarcinoma Cells Migration by Inhibiting Matrix Metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt Signaling Pathways. Evid Based Complement Alternat Med: pp. 2012: 378415. PubMed: 22454661.
47. Yeh CB, Hsieh MJ, Hsieh YH, Chien MH, Chiou HL, et al. (2012) Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity. PLOS ONE 7: e31055. doi:10.1371/journal.pone.0031055. PubMed: 22363545.
48. Li Z, Li C, Du L, Zhou Y, Wu W, (2013) Human chorionic gonadotropin beta induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells. PLOS ONE 8: e54592. doi:10.1371/journal.pone.0054592. PubMed: 23424616.
49. Liang KC, Lee CW, Lin WN, Lin CC, Wu CB, et al. (2007) Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 211: 759-770. doi:10.1002/jcp.20992. PubMed: 17311279.
50. Anderson NG, Maller JL, Tonks NK, Sturgill TW, (1990) Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343: 651-653. doi:10.1038/343651a0. PubMed: 2154696.
51. Seger R, Ahn NG, Posada J, Munar ES, Jensen AM, et al. (1992) Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 267: 14373-14381. PubMed: 1321146.